LUCIDITY phase 3 topline data presented at CTAD for HMTM – the only oral anti-Tau therapy in late-stage development
- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities
- Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimers Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco
- For people with early Alzheimers (MCI), HMTM improvement in cognition over pre-treatment baseline now shown to be sustained over 18 months
TauRx Pharmaceuticals Ltd is a global leader in Tau-based research…